Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Bridget Shaw 0121 414 2996
farrms@trials.bham.ac.uk


Emma Gray 0121 414 3799
farrms@trials.bham.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Back

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting

Open to: ALL

Age: All

Manchester Sutton Sheffield London Bristol Southampton Nottingham Oxford London Cambridge Leeds Leicester Liverpool Glasgow Sheffield Manchester Birmingham Belfast Bristol Leeds Wirral Newcastle Upon Tyne Aberdeen Belfast Birmingham Cardiff Cardiff Edinburgh Glasgow Nottingham London

Medical Conditions

Rhabdomyosarcoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2020 Jun 2030

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : antineoplastic enzyme inhibitor

Intervention Arm Group : CT1A: VHR Induction IRIVA;CT1B: HR Induction IRIVA;CT3: Relapsed Chemotherapy - VIRR;CT3: Relpased Chemotherapy - VIRT;Phase 1b Dose finding: VHR induction - IRIVA;

Intervention Type : DRUG
Intervention Description : Antineoplastic agent that is a polypeptide antibiotic

Intervention Arm Group : CT1A: VHR Induction IRIVA;CT1A: VHR induction - IVADO;CT1B: HR Induction IRIVA;CT1B: HR Induction IVA;Phase 1b Dose finding: VHR induction - IRIVA;

Intervention Type : DRUG
Intervention Description : An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius

Intervention Arm Group : CT1A: VHR induction - IVADO;

Intervention Type : DRUG
Intervention Description : chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide

Intervention Arm Group : CT1A: VHR Induction IRIVA;CT1A: VHR induction - IVADO;CT1B: HR Induction IRIVA;CT1B: HR Induction IVA;Phase 1b Dose finding: VHR induction - IRIVA;

Intervention Type : DRUG
Intervention Description : anti neoplastic vinca alkaloid agent

Intervention Arm Group : CT1A: VHR Induction IRIVA;CT1A: VHR induction - IVADO;CT1B: HR Induction IRIVA;CT1B: HR Induction IVA;CT3: Relapsed Chemotherapy - VIRR;CT3: Relpased Chemotherapy - VIRT;Phase 1b Dose finding: VHR induction - IRIVA;

Intervention Type : DRUG
Intervention Description : vinca alkaloid with a role as an antineoplastic agent

Intervention Arm Group : CT2A: VHR Maintenance - VC;CT2B: HR Maintenance - VC;

Intervention Type : DRUG
Intervention Description : Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent

Intervention Arm Group : CT2A: VHR Maintenance - VC;CT2B: HR Maintenance - VC;

Intervention Type : DRUG
Intervention Description : oral antineoplastic alkylating agent

Intervention Arm Group : CT3: Relpased Chemotherapy - VIRT;

Intervention Type : RADIATION
Intervention Description : Ionising radiation

Intervention Arm Group : RT1A: Post operative radiotherapy;RT1A: Preoperative Radiotherapy;RT1B: Radiotherapy for resectable disease: dose escalated;RT1B: Radiotherapy for resectable disease: standard dose;RT1C: Radiotherapy for unresectable disease: dose escalated;RT1C: Radiotherapy for unresectable disease: standard dose;RT2: Radiotherapy to all metastatic sites;RT2: Radiotherapy to primary tumour and involved lymph nodes;

Intervention Type : DRUG
Intervention Description : Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).

Intervention Arm Group : CT3: Relapsed Chemotherapy - VIRR;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Manchester Children's Hospital
    Manchester
    M13 9WL
  • Royal Marsden Hospital
    Sutton
    Surrey
    SM2 5PT
  • Sheffield Children's Hospital
    Sheffield
  • University College London Hospital
    London
  • Bristol Royal Hospital For Children
    Bristol
  • Southampton General Hospital
    Southampton
  • Nottingham City Hospital
    Nottingham
  • John Radcliffe Hospital
    Oxford
  • Great Ormond Street Hospital for Children
    London
  • Addenbrooke's Hospital
    Cambridge
  • Leeds General Infirmary
    Leeds
  • Leicester Royal Infirmary
    Leicester
  • Alder Hey Children's Hospital
    Liverpool
  • Beatson West of Scotland Cancer Centre
    Glasgow
  • Weston Park Hospital
    Sheffield
  • Christie Hospital
    Manchester
  • Birmingham Children's Hospital
    Birmingham
  • Belfast City Hospital
    Belfast
  • Bristol Haematology and Oncology Centre
    Bristol
  • St James's University Hospital
    Leeds
  • Clatterbridge Cancer Centre
    Wirral
  • Royal Victoria Infirmary
    Newcastle Upon Tyne
  • Royal Aberdeen Children's Hospital
    Aberdeen
  • Royal Belfast Hospital for Sick Children
    Belfast
  • The Queen Elizabeth Hospital
    Birmingham
  • Noah's Ark Children's Hospital for Wales
    Cardiff
  • Velindre Hospital
    Cardiff
  • Royal Hospital for Children and Young People
    Edinburgh
  • Royal Hospital for Children Glasgow
    Glasgow
  • Queen's Medical Centre, Nottingham
    Nottingham
  • Royal Marsden Hospital London
    London

Bridget Shaw 0121 414 2996
farrms@trials.bham.ac.uk


Emma Gray 0121 414 3799
farrms@trials.bham.ac.uk



The study is sponsored by University of Birmingham



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04625907
Last updated 22 May 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top